Semaglutide and Fertility: What Women Over 35 Need to Know

Why Obesity Affects Fertility

Obesity is one of the most significant but treatable causes of female infertility. Excess adipose tissue produces excess estrogen through peripheral aromatization, disrupting the hypothalamic-pituitary-ovarian (HPO) axis that governs the menstrual cycle. This can result in irregular or absent ovulation, polycystic ovarian syndrome (PCOS), implantation failure, and increased miscarriage risk. For women over 35 — where ovarian reserve is naturally declining — the additional burden of obesity-related hormonal disruption can make natural conception significantly more difficult.

The Positive Effect of Weight Loss on Fertility

The good news is that even modest weight loss — as little as 5–10% of body weight — can meaningfully restore ovulatory function in women with obesity-related anovulation. Clinical data consistently demonstrates:

• Restoration of regular menstrual cycles in women with obesity-related amenorrhea
• Improved ovulation rates — weight loss improves the LH/FSH ratio and reduces androgen excess
• Better IVF outcomes — lower BMI at the time of IVF is associated with higher egg quality, better fertilization rates, and improved live birth rates
• Reduced miscarriage risk — obesity is an independent risk factor for early pregnancy loss; weight normalization reduces this risk
• PCOS symptom improvement — GLP-1 therapy shows particular promise for PCOS-related infertility, with improvements in insulin resistance and androgen levels

Is Semaglutide Safe During Pregnancy?

No. Semaglutide is classified as Pregnancy Category X — contraindicated during pregnancy. Animal studies showed adverse fetal outcomes at clinically relevant doses, and while human safety data is limited, the potential risk is considered unacceptable given that weight loss during pregnancy is not recommended. If you are actively trying to conceive, you should discontinue semaglutide at least 2 months before attempting conception. This washout period allows the medication to clear from your system before potential conception.

Strategic Use: Lose Weight First, Then Conceive

For women over 35 who are overweight or obese and planning a future pregnancy, semaglutide can be used strategically as a pre-conception weight loss tool. The approach: use semaglutide to achieve meaningful weight loss and metabolic improvements, then discontinue with appropriate washout, then attempt conception at a healthier BMI. This "treat, then proceed" strategy may actually improve fertility outcomes compared to attempting conception at a higher BMI without intervention.

Semaglutide and Contraception: An Important Warning

GLP-1 receptor agonists may reduce the absorption of oral contraceptive pills by slowing gastric emptying. If you are taking oral birth control pills while on semaglutide, there is a theoretical reduction in contraceptive efficacy, particularly during the initial dose titration phase. Your gynecologist may recommend switching to a non-oral contraceptive method (IUD, implant, injection, patch) while on semaglutide therapy. Discuss this with both your Cora provider and your gynecologist.

Practical Guidance: Coordinating Care

For women over 35 considering semaglutide with future fertility in mind, this checklist helps coordinate appropriate care:

• Disclose your fertility goals to your Cora physician during the intake process
• Work with a reproductive endocrinologist to assess your current ovarian reserve (AMH, antral follicle count)
• Set a clear target BMI or weight loss goal before attempting conception
• Plan your medication discontinuation timeline with your provider — stop at least 2 months before you plan to start trying
• Continue prenatal vitamins (especially folate) throughout your semaglutide treatment period
• If you are already undergoing IVF, discuss timing of semaglutide with your reproductive endocrinologist before starting